The neurochemical circuitry of schizophrenia

Pharmacopsychiatry

Volumn 39, Issue SUPPL. 1, 2006, Pages

  Carlsson, Arvid ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; NORADRENALIN; PHENCYCLIDINE; SEROTONIN;

ARTICLE; BASAL GANGLION; BRAIN; DOPAMINERGIC ACTIVITY; FEEDBACK SYSTEM; HUMAN; HYPOTHESIS; MODEL; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; NERVE NET; NEURAL NETWORKS (COMPUTER); NEUROTRANSMITTER AGENTS; NONLINEAR DYNAMICS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33644827689     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931483     Document Type: Article

References (7)

1. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186
2. Carlsson A. The dopamine theory revisited. In: Hirsch SR and Weinberger DR (eds). Schizophrenia Oxford: Blackwell Science, 1995: pp 379-400
3. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-276
4. Carlsson M, Carlsson A. Dopaminergic stabilisers. Adv in Schizophrenia and Clin Psychiatry 2005; 1(4): 118-128
5. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia - therapeutic implications. Eur Arch Psychiat Clin Neurosci 1999; Suppl 4: 37-43
6. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41: 237-60
7. Sesack SR. Synaptology of dopamine neurons. In: Di Chiara G (ed). Handbook of Exper Pharmacol Vol 154/I Springer, Berlin: 2002: pp 63-119